BRCA2 and ovarian carcinoma: Additionally, testing the BRCA2 mutation could guide doctors to use rucaparib (a type of poly ADP-ribose polymerase inhibitor, PARPi) for the treatment of patients with advanced ovarian cancer and metastatic castration-resistant prostate cancer (63).